Endocrine Abstracts

Background: When seeing patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in clinic, we noticed that a significant proportion of our patients also had additional primary malignancies. This observation was also raised by patients at our local NET Patient Foundation support group. The idea that patients with GEP-NETs are more prone to additional malignancies is supported in the literature therefore we wanted to determine the proportion of our patients who ha...

Case: A 62 year old man was admitted acutely with right sided abdominal pain. A CT scan with contrast showed an acute right-sided adrenal haemorrhage with adjacent necrotic lymphadenopathy and multiple pulmonary nodules. An MRI, requested to further define the lesion, reported a malignant looking 7.4 cm right adrenal mass with direct focal invasion into the liver and inferior vena cava however no further liver lesions were identified. The images were discussed at the multi-dis...

Neuroendocrine tumours (NETs) are rare cancers originating from neuroendocrine cells. The estimated prevalence is 35 per 100,000 people per year. A comparative review was conducted at the University Hospitals of Leicester (UHL) to determine the outcomes of treated neuroendocrine patients.Methods: Patients were identified via pharmacy records of Lanreotide, from April 2009 – March 2018. Clinical data was obtained from hospital notes and histopatholog...

Introduction: Choline PET-CT is a recognised modality for imaging prostate cancer; both for initial staging and restaging. It is, however, a non specific tracer and is also positive in numerous other conditions such as inflammatory processes and other malignancies.Method: We present a case of a 60 year old patient with a PSA of 9 ng/ml and a firm abnormal right prostate lobe. Prostate MRI demonstrated a lesion in the apex of the prostate but no associate...

Introduction: There is a clinical need to develop novel and better biomarkers to monitor patients with neuroendocrine neoplasms (NENs). Our aim was to identify and track plasma circulating cell free tumour derived DNA (ctDNA) in a cohort of patients using a personalised, patient specific approach.Materials and methods: 35 serial plasma samples were collected from 9 patients with metastatic NENs (6 small intestinal and 1 each of lung, ovarian, and pelvic;...